Harrow Health - HROW Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Harrow Health in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" HROW shares.
View HROW analyst ratings or view top-rated stocks.

2 equities research analysts have issued 12-month target prices for Harrow Health's shares. Their HROW share price forecasts range from $15.00 to $20.00. On average, they expect the company's share price to reach $17.50 in the next twelve months. This suggests a possible upside of 104.9% from the stock's current price.
View analysts price targets for HROW or view top-rated stocks among Wall Street analysts.

Harrow Health's stock was trading at $8.64 at the beginning of 2022. Since then, HROW stock has decreased by 1.2% and is now trading at $8.54.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our HROW earnings forecast.

Harrow Health, Inc. (NASDAQ:HROW) announced its quarterly earnings results on Tuesday, November, 9th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of $0.03 by $0.34. The company earned $18.71 million during the quarter, compared to the consensus estimate of $17.27 million. Harrow Health had a positive trailing twelve-month return on equity of 15.04% and a negative net margin of 28.96%. During the same quarter in the previous year, the business posted $0.32 EPS.

Based on aggregate information from My MarketBeat watchlists, some companies that other Harrow Health investors own include NVIDIA (NVDA), Aldeyra Therapeutics (ALDX), OPKO Health (OPK), QUALCOMM (QCOM), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY), VBI Vaccines (VBIV), Exelixis (EXEL) and Mustang Bio (MBIO).

Harrow Health trades on the NASDAQ under the ticker symbol "HROW."

Harrow Health's stock is owned by a number of institutional and retail investors. Top institutional investors include Ophir Asset Management Pty Ltd (5.48%), Acuitas Investments LLC (1.09%), Anchor Capital Advisors LLC (0.84%), Westside Investment Management Inc. (0.73%), Assenagon Asset Management S.A. (0.49%) and Russell Investments Group Ltd. (0.45%). Insiders that own company stock include David P Kennedy, Opaleye Management Inc, Richard L Md Lindstrom, Richard L Md Lindstrom and Robert J Kammer.
View institutional ownership trends.

Shares of HROW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of HROW stock can currently be purchased for approximately $8.54.

Harrow Health (NASDAQ:HROW) has a market capitalization of $230.84 million and generates $72.48 million in revenue each year. The company earns $-18,010,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis.

The company employs 182 workers across the globe.

Harrow Health's mailing address is 102 Woodmont Blvd. Suite 610, Nashville TN, 37205. The official website for the company is www.harrowinc.com. The company can be reached via phone at (615) 733-4730, via email at jpatton@harrowinc.com, or via fax at 858-345-1745.